Intraarterial Verapamil for Neuroprotection in Ischemic Stroke
Global Neurosciences Institute
Summary
The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.
Eligibility
- Age range
- 18–80 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Written informed consent * 18 years of age and over * Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia * Candidate for mechanical thrombectomy procedure * Onset of symptoms less than 8 hours * Measurable neurologic deficit (NIHSS ≥4) * Willingness to follow up with rehabilitation therapy * Anticipated life expectancy of at least 3 months Exclusion Criteria: * Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential) * Hepatic and/or r…
Interventions
- Drug10 mg Intra-arterial Verapamil
Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
- Drug20 mg Intra-arterial Verapamil
Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
Locations (3)
- AtlantiCare Regional Medical CenterAtlantic City, New Jersey
- St Mary Medical CenterLanghorne, Pennsylvania
- Crozer Chester Medical CenterUpland, Pennsylvania